Firm will seek approval of a range of diagnostic assays for the platform. Qiagen confirmed the receipt or FDA 510(k) clearance for both its Rotor-Gene Q MDx real-time PCR platform, and also the artus ...
Qiagen NV, a leading global provider of sample & assay technologies, has received the two US Food and Drug Administration (FDA) 510(k) clearances for its real-time PCR (polymerase chain reaction) ...
QIAGEN to develop PCR test to detect isocitrate dehydrogenase-1 (IDH1) mutations in AML patients to be used with Servier’s marketed and investigational targeted treatment Test for blood and bone ...
VENLO, the Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback